{"id":"02369","slug":"b7-h3-monoclonal-antibody-and--02369","source":{"id":"02369","dataset":"techtransfer","title":"B7-H3 Monoclonal Antibody and Methods of Use Thereof","description_":"<p>The technology centers on a B7-H3-specific monoclonal antibody, mAb 376.96, designed to target an epitope predominantly expressed on malignant cells. Detailed studies have validated its unique binding characteristics through both in vitro and in vivo experiments, confirming its high specificity and potential utility in cancer research, diagnostics, and therapeutics. Its development, built on extensive university research, reflects a sophisticated process that ensures the antibody’s precise affinity for the intended B7-H3 antigen, offering promise for more targeted interventions.</p><p><h2>Description</h2>This technology distinguishes itself by its rigorous characterization and validated in vivo efficacy, setting it apart from earlier, less-defined antibodies. The clear delineation of its epitope-specific binding enables enhanced targeting of malignant cells while potentially reducing collateral effects on healthy tissues. Commercial interest, as indicated by industry players like ImmunGene, further underlines its innovative edge in the competitive field of cancer treatment development, positioning it as a promising candidate for advancing precision medicine initiatives in oncology.</p><p><h2>Applications</h2>- Cancer targeted therapy\r<br>- Tumor diagnostic imaging\r<br>- Cancer biomarker detection\r<br>- Immuno-oncology research tool</p><p><h2>Advantages</h2>- Enhanced targeting: Specifically binds malignant cells while sparing healthy tissue.\r<br>- Diagnostic and therapeutic potential: Offers advancements in cancer detection and treatment.\r<br>- In vivo validation: Demonstrated efficacy in animal studies supports real-world applications.\r<br>- Improved specificity: Provides a more accurately-characterized antibody compared to earlier versions.</p><p></p><p><h2>IP Status</h2>Research Tool</p><p></p>","tags":[],"file_number":"02369","collections":[],"meta_description":"B7-H3 antibody mAb 376.96 targets malignant cells with high specificity, enabling cancer therapy, diagnostics, and research tools.","image_url":"","apriori_judge_output":"{\"scores\":{\"novelty\":2.0,\"potential_impact\":3.0,\"readiness\":2.0,\"scalability\":2.0,\"timeliness\":1.0},\"weighted_score\":1.9,\"risks\":[\"Old (2011) IP/technology readiness likely outdated for modern translational path\",\"Limited data on Phase/clinical validation\",\"Research tool status may limit immediate therapeutic/diagnostic deployment\",\"Potential regulatory/manufacturing challenges for mAb format\"],\"one_sentence_take\":\"The concept shows solid foundational biology but is hampered by age, limited translational validation, and tool-status IP, yielding modest weighted potential.\"}","lead_inventor_name":"Soldano Ferrone","lead_inventor_dept":"Department of Surgery","technology_type":"Life Science Research Tool","technology_subtype":"Protein","therapeutic_areas":[],"therapeutic_indications":[],"custom_tags":[],"all_tech_innovators":["Soldano Ferrone","Xinhui Wang MD, PhD"],"date_submitted":"2011-01-04"},"highlight":{},"matched_queries":null,"score":0.0}